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The role of the lymphatic system
in cholesterol transport
Li-Hao Huang*, Andrew Elvington and Gwendalyn J. Randolph*
Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
Reverse cholesterol transport (RCT) is the pathway for removal of peripheral tissue
cholesterol and involves transport of cholesterol back to liver for excretion, starting
from cellular cholesterol efflux facilitated by lipid-free apolipoprotein A1 (ApoA1) or other
lipidated high-density lipoprotein (HDL) particles within the interstitial space. Extracellular
cholesterol then is picked up and transported through the lymphatic vasculature before
entering into bloodstream. There is increasing evidence supporting a role for enhanced
macrophage cholesterol efflux and RCT in ameliorating atherosclerosis, and recent data
suggest that these processes may serve as better diagnostic biomarkers than plasma
HDL levels. Hence, it is important to better understand the processes governing ApoA1
and HDL influx into peripheral tissues from the bloodstream, modification and facilitation
of cellular cholesterol removal within the interstitial space, and transport through the
lymphatic vasculature. New findings will complement therapeutic strategies for the
treatment of atherosclerotic vascular disease.
Keywords: lymphatics, cholesterol reverse transport, cholesterol efflux, atherosclerosis, high-density lipoprotein
transport, high-density lipoprotein modification, interstitial space, apolipoprotein A1
Introduction
Lipoproteins are important vehicles to transport hydrophobic lipids in the circulation of the human
body. They contain various lipids complexed with specific apolipoproteins, which function as
a ligand for transporters expressed in tissues and to maintain the structural properties of the
lipoprotein particles. Lipoproteins can be distinguished based on their particle size and density.
Forward cholesterol transport starts from very low-density lipoproteins (VLDLs), which mainly
contain triglycerides and a small amount of cholesteryl esters and free cholesterol. They are exported
from the liver and delivered to peripheral tissues for use (Figure 1). After removal of triglyceride
content by lipoprotein lipases, VLDLs are converted to smaller intermediate-density lipoproteins
(IDLs) and low-density lipoproteins (LDLs). LDLs account for the majority of cholesterol delivered
to peripheral tissue for usage (Figure 1; Hewing and Landmesser, 2015). In order to remove
excess cholesterol content from peripheral tissues, cellular cholesterol is removed, passed to
the liver and packaged in bile salts for ultimate excretion, a process called reverse cholesterol
transport (RCT; Figure 1). The initial step in RCT is the efflux of cellular cholesterol, mediated
by ATP-binding cassette (ABC) transporters expressed on the cell, to complex with apolipoprotein
A1 (ApoA1) to form nascent high-density lipoprotein (HDL) particles. This initial step occurs
within the interstitial space, where nutrients and waste products are exchanged between cells
and capillaries (Figure 1). The composition and properties of the interstitial fluid varies between
tissues and is modulated in response to physiological and pathophysiological conditions (Hansen
et al., 2015). Dating back to mid-1970s, an inverse relationship was reported between the plasma
concentration of HDL cholesterol and the risk of a detrimental cardiovascular event. Unfortunately,
strategies that effectively raise plasma HDL levels, such as cholesteryl ester transfer protein
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FIGURE 1 | Forward and reverse cholesterol transport. The forward cholesterol transport starts from the liver, which generates triglyceride-rich verylow-density
lipoprotein (VLDL) and releases it into circulation. VLDL is progressively hydrolyzed and forms intermediate and low-density lipoproteins (IDL, LDL). LDL, as a major
cholesterol carrier, serves to transport cholesterol to peripheral tissues to use through LDL receptor (LDLR). To remove the excess accumulated cholesterol from
peripheral tissues, cholesterol is transported through lymphatics, veins, and back to the liver for excretion, a process called reverse cholesterol transport (RCT). The
high-density lipoprotein (HDL) plays an important role in removing cholesterol through RCT. Lipid free ApoA1 picks up free cholesterol from peripheral cells through
ATP binding cassette transporter A1 (ABCA1) and forms preb-HDL. Preb-HDL travels through lymphatics to the vein, where preb-HDL can be further modified to
become a-HDL and removed through direct uptake by HDL receptor, scavenger receptor B1 (SR-B1).
(CETP) inhibitors and niacin, have not reduced clinical
cardiovascular events. Despite experimental evidence that HDL
particles function in an anti-atherosclerotic manner (Plump
et al., 1994; Rosenson et al., 2012), clinical studies have failed
to demonstrate that plasma HDL concentrations are directly
correlated with and regulate atherogenesis.
We propose that in order to better understand why elevating
plasma HDL concentrations do not always comprise an
efficacious cardiovascular disease (CVD) therapy, one must
understand the different compartments in which HDL localizes.
HDL concentration, composition, and modification is different
in the interstitial space as compared to plasma HDL. Miller
et al. (1976) theorized in 1976 that the lymphatic vasculature
could be the main transit route for movement of HDL from the
interstitial space to the bloodstream and liver. Experimental
evidence supports this suggestion: surgical or genetic disruption
of lymphatic vasculature in the skin of mice markedly reduces
the appearance of labeled cholesterol in plasma that originated
from implanted tissue macrophages (Lim et al., 2013; Martel
et al., 2013). Therefore, a better understanding of how HDL
is formed, how it gains access to peripheral tissues, how it is
modified in the interstitial space and in lymphatic vessels, and
finally is transported through lymphatics to the liver for excretion
is essential to the development of novel HDL-based therapeutics
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to prevent or ameliorate CVD. This review discusses current
clinical findings related to RCT, HDL transport and modification
in the interstitial space, and the role of the lymphatic system in
RCT, and identifies potentially important questions for future
research.
The HDL Hypothesis Needs Revision
Many human epidemiological studies demonstrate a strong
inverse association of plasma levels of HDL cholesterol and
coronary heart disease (CHD), which suggest that raising HDL
cholesterol levels may decrease risk of CVD (Barter et al., 2007a;
Singh et al., 2007). Independent of LDL concentration, a 1%
increase in the concentration of HDL cholesterol reduced CHD
events 0.6% (Gordon et al., 1986). In the Helsinki Heart Study,
an increase in HDL cholesterol, together with a decrease in
LDL cholesterol concentration, was significantly associated with
decreased in CHD events, independent of other risk factors
(Manninen et al., 1988). While promising, several recent clinical
trials aiming to increase HDL cholesterol levels failed to support
these early findings. In randomized trials, despite significantly
increasedHDL cholesterol in the plasma, treatment with niacin or
CETP inhibitors did not improve cardiovascular outcomes (Barter
et al., 2007b; AIM-HIGH Investigators et al., 2011; Schwartz
et al., 2012; HPS2-THRIVE Collaborative Group et al., 2014;
Keene et al., 2014). One can argue that the effects of niacin were
confounded by concurrent statin treatment and that taking niacin
alone would be associated with a decreased rate of non-fatal
myocardial infarction. Even so, niacin itself also decreases LDL
cholesterol so that reduced non-fatal myocardial infarction events
might be simply interpreted as being due to reduced LDL (Keene
et al., 2014). Thus, trials using pharmaceutical interventions to
test the HDL hypothesis have caveats, and the conclusions remain
unclear. A more specific strategy of using ApoA1/HDL mimetics
was developed and used to test HDL cholesterol effects on
CVD (Kingwell and Chapman, 2013). Unfortunately, a phase 2b
randomized trial with the HDL-mimetic CER-001 demonstrated
no significant difference in plaque regression between treated
and non-treated groups (Tardif et al., 2014). Human genetic
studies showed that genes regulating cholesterol levels are poorly
correlated with protection from vascular diseases (Voight et al.,
2012). Another human genetic study showed that an endothelial
lipase variant, N396S, raised HDL cholesterol levels, but was not
associated with decreased CVD (Voight et al., 2012). Inversely, the
ApoA1 milano mutation, which creates a disulfide bond in the c-
terminus facilitating increased lipid recruitment relative to WT
ApoA1 (Gursky et al., 2013), does not lead to any increase in CVD
even though carriers display very low plasma HDL cholesterol
levels (Favari et al., 2007).
Cellular Cholesterol Efflux and
Cardiovascular Diseases
The consequences of dysfunctional cellular cholesterol efflux are
best observed in the context of the pathophysiology of CVDs.
Khera et al. (2011) reported that in vitro cellular cholesterol
efflux capacity, assessed by an assay originally developed by
Rothblat et al. (1999), was strongly inversely associated with CVD,
consistent with the experimental outcomes demonstrating HDL
is atheroprotective by facilitating cholesterol efflux from foamy
macrophages. The authors conclude that cellular cholesterol
efflux capacity is a more accurate biomarker for CVD than
plasma HDL cholesterol levels (Khera et al., 2011). Furthermore,
Rohatgi et al. (2014) showed that cholesterol efflux capacity was
inversely associated with CVD after adjusting for the traditional
risk factors, HDL cholesterol levels, and particle concentration,
suggesting that cholesterol efflux capacity is a new biomarker
for CVDs. Paradoxically, Li et al. (2013) observed that higher
cholesterol efflux capacity correlated with increased morbidity
and mortality of incident CVD, such as myocardial infarction
and stroke. In line with this finding, metabolic diseases that
are risk factors for CVD, such as type IV hyper-triglyceridemic
and Type II diabetes, also showed higher cholesterol efflux from
foamy macrophages through the ABC transporter A1 (ABCA1)
dependent pathway (Attia et al., 2008), likely due to elevated
triglycerides (Yassine et al., 2014). One speculative but attractive
explanation for the puzzling results by Li et al. (2013) is that
although the individuals under study had high plasma HDL, they
also bore physiological alterations that led to poor cycling of
HDL (Randolph and Miller, 2014). In this scenario, plasma HDL
would appear quite functional in vitro, but in vivo it may not be
located or functional in the extravascular spaces where its action is
required, and genome-wide association study (GWAS) finds that
HDL transport pathway is associated with coronary artery disease
patients (Ghosh et al., 2015). In the next sections, we will review
the important trafficking properties of HDL that are essential to
its function.
Mechanisms for Removal of Cellular
Cholesterol
Cells store cholesterol, esterified to fatty acids, in the form of lipid
droplets. Cells cannot catabolize cholesterol, and thus to prevent
toxicity resulting from excessive accumulation, cellular free
cholesterol from peripheral tissues must be removed (Yokoyama,
2005). One means of removing cholesterol from the bioactive
pool is to form cholesteryl esters that are stored as lipid droplets
inside of affected cells. The enzymes that esterify fatty acids to
cholesterol are acyl-CoA: cholesterol acyltransferase 1 (ACAT1)
and ACAT2 (Chang et al., 2009). Beyond esterification, free
cholesterol can be physically removed from cells by passive
(non-specific) diffusion or by apolipoprotein-mediated removal.
Passive diffusion is a non-specific process between cell surface
and extracellular acceptor, such as HDL. Passive diffusion of
cholesterol can be enhanced via involvement of scavenger receptor
B1 (SR-B1; Ji et al., 1997), and evidence demonstrates that
ABC transporter G1 (ABCG1) can facilitate formation of mature
HDL via passive diffusion (Kennedy et al., 2005). However, the
more efficient cholesterol efflux mechanism is mediated through
apolipoproteins. ABCA1, located on the plasmamembrane (Wang
et al., 2004), facilitates the generation of disk-like nascent HDL
particles using cellular phospholipids, cholesterol, and lipid-poor
ApoA1. While outside of the scope of this review, in depth
discussion of the mechanisms of cellular cholesterol efflux has
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been expertly reviewed elsewhere (Phillips, 2014;Westerterp et al.,
2014). AlthoughHDL functions as a dedicated lipoprotein particle
for accepting cholesterol, LDL, VLDL and liposomes may serve
as alternative cholesterol acceptors (Tarling and Edwards, 2011).
However, less LDL andVLDL passes into the interstitium as intact
particles because they are larger than HDL (Michel et al., 2015).
Reverse Cholesterol Transport and HDL
Metabolism
HDL particles can be modified or removed from plasma in a
variety of different ways. The major protein of HDL particles,
ApoA1 (75%), is synthesized by the liver (70%) and also by
the small intestine (30%). ApoA-II comprises about 20–25%
of proteins in HDL. Nascent HDL particles produced from
lipid-poor ApoA1 through ABCA1 expressed in hepatocytes
and enterocytes can be further modified to form mature HDL
through the enzyme lecithin cholesteryl acyltransferase (LCAT).
LCAT esterifies cholesterol to form cholesteryl ester, the core
of the mature particle. Another enzyme that is also able to
modify HDL is the phospholipid transfer protein (PLTP). PLTP
liberates phospholipid from apolipoprotein B (ApoB) containing
lipoproteins like VLDL and LDL and transfers them to HDL,
even as it also mediates HDL particle fusion to form larger
HDL particles as well as some preb-HDL. In PLTP /  mouse,
HDL and ApoA1 levels are significantly decreased. The presence
of preb-HDL in PLTP /  mouse is much lower compared to
the wild-type control (17% of that in wild-type; Jiang et al.,
1999). HDL particles can be metabolized by the exchange of
approximate equimolar of triglycerides with a cholesteryl ester to
ApoB-containing lipoproteins, such as LDL and VLDL, by CETP
in plasma (Tall, 1993). HDL can also be remodeled by various
lipases, such as hepatic lipase or endothelial lipase, to form smaller
HDL particles susceptible to faster catabolism. Finally, the major
site of HDL cholesteryl ester uptake is the liver, accounting for
65% of the total, through HDL receptor, SR-B1 (Glass et al., 1983;
Brunham and Hayden, 2015). The kidney accounts for 18% of
total uptake of ApoA1 that contains <1% no cholesterol ester
(Glass et al., 1983). Free ApoA1 is filtered through glomerular
filtration and catabolized by proximal renal tubular epithelial cells.
With all thesemechanisms operatingwithin plasma to regulate the
composition and removal of HDL, it is easy to forget that the key
role for HDL is to relocate from the plasma to the extravascular
interstitium, where it can carry out its role in accepting cholesterol
from cells in extravascular spaces.
HDL Transport From Plasma to Lymph
While HDL is measured in the plasma, much of the life cycle
of HDL is spent within the tissue (Rudra et al., 1984; Miller
et al., 2013; Randolph and Miller, 2014) and its migration from
that tissue back to the blood compartment occurs via trafficking
through the lymphatic system. Radiolabeled cholesterol was
identified in the lymph and tissue compartments immediately
after i.v., administration in human patients (Reichl et al.,
1973). Several weeks following administration, radiolabeled tissue
cholesterol was higher in lymph than in plasma, indicating that
cholesterol in lymph was derived from plasma (Samuel et al.,
1972; Reichl et al., 1973). HDL particles have been proposed
to cross the vascular endothelium from plasma into interstitial
fluid through receptor-mediated transcytosis based on in vitro
studies (Rohrer et al., 2006) and/or passive diffusion through
intercellular pores (Nordestgaard and Nielsen, 1994; Michel
et al., 2015; Figure 2). Using aortic endothelial cells in vitro,
Cavelier et al. (2006) showed that lipid-free ApoA1 binds and is
internalized and transported in an ABCA1 dependent manner,
generating lipidated particles through this process. Also using
aortic endothelial cells in vitro, Rohrer et al. (2009) demonstrated
HDL particles bind, are internalized, and are transported in
a SR-B1 and ABCG1, but not ABCA1, dependent process,
reducing particle size without degrading the protein moiety.
However, in rabbits fed a high cholesterol diet, the influx into the
arterial space of plasma lipoproteins, such as LDL, VLDL, and
HDL, decreases linearly with the logarithm of particle diameter
(Stender and Zilversmit, 1981), suggesting that lipoproteins cross
the endothelium in a size-dependent manner. Michel et al.
(2015) demonstrated in vivo that HDL and LDL transport from
the plasma to the interstitial space occurs passively through
endothelial intercellular pores and that active receptor-mediated
transcytosis is unnecessary. If transport is predominantly passive,
particle size would be expected to limit the transfer rate. Indeed,
studies indicate that an HDL size increase from average 4.5–6 nm
lowers its clearance rate by 12% (Michel et al., 2015). When
vascular permeability is increased, influx of HDL into interstitial
fluid is enhanced, and the rate of RCT is increased. The result
supports the observation of the importance of passive HDL
transport (Kareinen et al., 2015). Adenoviral overexpression of
PLTP in hepatocytes generates larger particle size (<7.1 nm but
larger than lipid-free ApoA1; Ji et al., 2014) and also increases
atherosclerotic lesion size in PLTP overexpressing ApoE deficient
mice (Zhang et al., 2014), although the causal relationship
between PLTP and CVD is still under debate (Vergeer et al.,
2010; Kim et al., 2015). In line with the mechanism proposed
by Zhang et al. (2014), the increased HDL particle size resulting
from PLTP overexpression impaired RCT (Samyn et al., 2009),
perhaps impairing movement of HDL into the interstitium,
limiting cholesterol uptake from extravascular spaces like plaque,
and ultimately increasing atherosclerotic disease progression.
Whether increased HDL particle size affects HDL transport
and/or RCT requires further investigation.
The Lymphatic System and its Functions
Once in the interstitium, HDL picks up cellular cholesterol and,
to complete its job, must return to plasma. HDL appears to return
back to the plasma compartment via movement through the
lymphatic network that has evolved to manage and prevent fluid
accumulation in tissues. Starling (1896) proposed that fluid flux
across the walls of blood capillaries was determined by differences
in blood pressure and colloid osmotic pressure between the
interstitial fluid and plasma. For example, on the arterial side
of the capillary bed, where the blood pressure (120 mmHg)
is higher than the colloid osmotic pressure, plasma constituents
continuously filter into the interstitial space. On the venous side
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FIGURE 2 | Lymphatic dependent reverse cholesterol transport within the peripheral tissues. HDL particles cross the vascular endothelium from
plasma into interstitial fluid. Lipid-poor ApoA1 facilitates cellular cholesterol efflux through ABCA1-mediated pathway to form preb-HDL. Lymphatic
capillaries have discontinuous “button-like” junctions, which are permeable for optimal fluid uptake. Lymphatic flow is driven by the pumping action of
downstream collecting lymphatic vessels (not depicted). Ultimately, lymph ends up in the thoracic duct that crosses the lymphovenous valve and drains into
the subclavian vein.
of the capillary bed, where the colloid osmotic pressure is higher
than the blood pressure, some interstitial fluid may be reabsorbed
as per Starling’s Law (Földi and Strössenreuther, 2005; Figure 2).
However, it is now thought the venous system has a much more
minor role than previously believed (Levick and Michel, 2010).
Lymphatic capillaries, blind-ended vessels composed of a single
layer of lymphatic endothelial cells (LECs) lacking a basement
matrix, also drain fluid from the interstitial space. It is important
to stress, however, that the lymphatics are not merely finishing the
task carried out by the venous system, but the lymphatic vessels
are able to take up and transport molecules (and cells) larger than
those that will readily traverse the venous wall. Molecules larger
in radius than tumor necrosis factor a (3.24 nm) are primarily
transported via the lymphatic vasculature (Miller et al., 2011)
and lipoproteins of course are much larger than this. Sorting of
lipoproteins for transport based on size was also raised by the
studies of Fraser et al. (2012) who argued that liver sinusoidal cells
create a semipermeable barrier, “liver sieve,” to sort colloidal sized
particles, prevent the uptake of chylomicrons and largeVLDL, and
permit the selective uptake of the remnant particles.
There is a structural basis for the ability of lymphatics to
transport larger molecules than the venous vasculature. Unlike
blood vessels, which have continuous inter-endothelial junctions,
lymphatic capillaries have discontinuous “button-like” junctions,
which are permeable for optimal fluid uptake (Baluk et al., 2007;
Tammela and Alitalo, 2010; Figure 2). From the capillaries, the
lymph flows into pre-collector lymphatic vessels and then into
collecting lymphatic vessels. Collecting lymphatic vessels are very
different from lymphatic capillaries in that they are surrounded
by smooth muscle cells (SMCs) with intrinsic contractile activity
that propels lymph (Muthuchamy and Zawieja, 2008) through
units called lymphangions that are separated by bi-leaflet valves to
prevent lymph backflow (Bazigou et al., 2009). Lymph propulsion
is also influenced by external arterial pulsations, such as skeletal
movements, interstitial pressure, and inflammatory responses, or
by internal nitric oxide (NO) synthesis produced by endothelial
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nitric oxide synthase (eNOS) from LECs (Kesler et al., 2013).
Ultimately, lymph is filtered through lymph nodes and the filtrate
ends up in the thoracic duct that drains into the subclavian vein
(Jeltsch et al., 2003). Lymphatic vessels exist in most tissues with
the exception of the eye (cornea and retina), bone marrow, and
brain parenchyma (Tammela and Alitalo, 2010). The brain does
contain an elegant system that promotes very active fluid transport
called the glymphatics (Iliff et al., 2013; Plog et al., 2015) and
very recently lymphatics in themeningeswere reported (Aspelund
et al., 2015; Louveau et al., 2015) that are thought to receive fluid
from the glymphatic system.
HDL Transport During Reverse Cholesterol
Transport Through Lymphatics
In the interstitial space, HDL becomes loaded with cellular
cholesterol, as the first step of RCT, for transport back to the
plasma compartment through the lymphatic system. Although
the idea that HDL removal from tissues would follow osmotic
flow of water into the lumen of venous capillaries (Perl, 1975)
seems highly unlikely based on the principles of higher molecular
weight molecules requiring lymphatics (Miller et al., 2011) and
impressive recovery of HDL in human afferent lymph (Nanjee
et al., 2000, 2001a,b;Miller et al., 2013), formal demonstration that
lymphatics mediated transit of HDL from tissue back into blood
has occurred only recently (Lim et al., 2013; Martel et al., 2013).
Surgical interruption of tail lymphatics significantly reduced
RCT, without altering the lipoprotein profile or macrophage
cholesterol efflux capacity (Martel et al., 2013). These findings
were replicated in a genetic mutant mouse model (Martel
et al., 2013), which lack dermal lymphatic capillaries due to
deficiency in one allele of vascular endothelial growth factor-
C receptor (VEGFR3; Karkkainen et al., 2001; Martel et al.,
2013). Furthermore, a surgical model of aortic arch transplant
was used to argue that cholesterol removal from plaques was also
dependent upon lymphatics (Martel et al., 2013). Models with
lymphatic disruption, such as the aortic transplant or surgical
disassociation, nicely demonstrate the necessity of lymphatics in
RCT. However, to eliminate potentially confounding factors such
asmodel inflammation, thesemechanisms need to be investigated
using non-surgical models.
HDL Composition and Modification in
Interstitial Space and in Lymph
Cholesterol concentration in the lymph is approximately a
tenth of the concentration in the plasma (Reichl et al., 1978).
As in the plasma, cholesterol in the lymph is transported by
apolipoproteins, such as ApoA1 and ApoB, although Reichl and
Pflug (1982) and Reichl et al. (1977)consistently found that
ApoA1 and ApoB concentrations in the lymph were much lower
than plasma concentrations (Sloop et al., 1983; Reichl et al.,
1991; Randolph and Miller, 2014). During passage from the
interstitial space to the lymph, Reichl et al. (1975) reported
that plasma lipoproteins undergo modifications, demonstrated
with radiolabeled apolipoproteins injected into male patients.
In his studies, men were given an i.v., injection of 131I-labeled
ApoB LDL, and 125I-labeled ApoA VLDL. Both 131I-labeled and
125I-labeled proteins appeared in the lymph. In lymph, 125I-
labeled ApoA-containing lipoproteins showed similar mobility
compared toApoA1 ofHDL in plasma, whereas 131I-labeledApoB
still remained with ApoB-containing lipoproteins, suggesting
that ApoA-containing lipoproteins undergo modification during
passage to the lymph (Reichl et al., 1975). The work of Reichl et al.
(1975) provided the foundation for further study into lipoprotein
remodeling within the interstitial fluid compared with plasma.
Incubation studies found that preb-HDLs were reduced in the
first phase of plasma incubation (Sloop et al., 1983), due to the
LCAT activity in plasma that esterifies free cholesterol of HDL
facilitating conversion to mature spherical HDL (Sloop et al.,
1983; Miller et al., 2013). Beyond 2 h of incubation in plasma,
preb-HDLs were recovered due to the further modification by
PLTP and CETP, which facilitate the exchange of lipids with
other lipoproteins (Sloop et al., 1983). In contrast, no reduction
of preb-HDLs were observed during incubation in human lymph
samples: contributing factors include higher specific activity of
PLTP, lower cholesterol esterification rate, and lower CETP
activity than observed in plasma (Miller et al., 2013). Relevant
to RCT, cholesterol removal from cells is most efficient with
small, dense HDL particles (Du et al., 2015). These findings,
together with previous observations (Castro and Fielding, 1988),
suggest a feasible physiological mechanism within the interstitial
space: increased conversion of preb-HDLs from a-HDLs in
the interstitial fluid makes more preb-HDLs in lymph, thereby
picking up available cholesterol from peripheral tissues/cells in an
ABCA1-dependent process (Castro and Fielding, 1988), leading
to the formation of discoidal HDLs (Figure 2).
Lymph apolipoprotein concentrations could vary depending
on cholesterol feeding. The ratios of ApoE/ApoA1 and
ApoAIV/ApoA1 in lymph HDL from control and cholesterol-fed
dogs is increased by sevenfold compared to plasma HDL (Sloop
et al., 1983). Upon discoidal HDLs entering the bloodstream
via the thoracic duct, further modifications can occur by LCAT
creating spheroidal a-HDLs with more cholesteryl esters in the
core (Sloop et al., 1983). Spheroidal a-HDLs can be catabolized
in the liver with direct uptake through HDL receptor, SR-B1,
or CETP can facilitate transfer of cholesteryl esters to ApoB-
containing lipoproteins, such as VLDL and LDL (Brunham and
Hayden, 2015). Modification of HDL within the interstitial space
and lymph may have a role in development of atherosclerosis,
though a better understanding of these modifications that may
be specific to the atherosclerotic plaque environment is needed.
Lymphatic Significance and Implication for
Cardiovascular Disease
The influx, oxidization, and retention of ApoB-containing
lipoproteins within the subendothelial space is a key aspect of
the initiation of atherosclerosis (Tabas et al., 2007). Recruitment
of monocytes, and differentiation into foamy macrophages,
drive disease progression (Gautier et al., 2009). As macrophages
phagocytize oxidized ApoB-containing lipoproteins, a fatty streak
is formed within the intimal layer of the vessel, serving as a
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FIGURE 3 | Lymphatic dependent reverse cholesterol transport within the atherosclerotic plaque. In the context of the atherosclerotic plaque
environment, removal of plaque cholesterol may be impaired by oxidation and modification of ApoA1 that prevents its ability to accept cholesterol from foam cells
to form HDL. Movement of the HDL-cholesterol out of plaques occurs in the direction of interstitial fluid flow with removal likely occurring in adventitial lymphatic
vessels.
marker for the early stage of disease. Foam cells are thought to
be inflammatory and necrosis of macrophages alongside invading
smooth muscle cells with altered differentiation (Shankman
et al., 2015) result in the formation of necrotic core and
cholesterol crystals (Glass and Witztum, 2001). Is there a role for
lymphatic vessels in plaque progression? A relationship between
atherosclerosis and reduced lymphatic transport of cholesterol
was hypothesized in the early 1980s (Lemole, 1981; Miller et al.,
1992). Lymphatic vessels were later identified within the arterial
wall (Johnson, 1969; Nakano et al., 2005; Drozdz et al., 2012).
In human diseased vessels, a positive correlation exists between
intimal thickness and adventitial lymphatic density (Drozdz
et al., 2008), as well as lymphatic dysfunction and atherogenesis
(Eliska et al., 2006). Perhaps these results can be interpreted
as evidence that lymphatics remodel to facilitate RCT from the
intimal environment. It remains unclear and imperfectly studied
as to how HDL cholesterol leaves the plaque, although flow
into lymphatics is experimentally supported (Martel et al., 2013)
and most consistent with physiological principles (Figure 3).
Specifically, Martel et al. (2013) transplanted plaque-laden
aortic arches that were loaded with stable isotope-cholesterol
into atherogenic recipient mice. Inhibition of the regrowth of
lymphatic vessels, by neutralizing anti-VEGFR3 mAb treatment,
impaired the efflux of cholesterol from the transplanted aortic
plaque tissue. Further study is warranted to delineate the nature
of the lymphatic system involvement in RCT from native plaque
in a less manipulated system. We propose that HDL accepts
cholesterol from plaque macrophages and then exits via the
lymphatic network, and that very few macrophages themselves
exit the plaque via lymphatics (Potteaux et al., 2011; Randolph,
2014; Figure 3). As mentioned earlier, to better clarify these
mechanisms, models are needed that can avoid some caveats,
one of which is the inherent inflammation of the surgical
procedure that can promote neo-lymphangiogenesis (Aebischer
et al., 2014).
One such model was utilized in a 2014 study by Vuorio et al.
(2014). By crossing sVEGFR3 and Chy transgenic mice, which
have insufficient lymphatics, with the atherogenic LDLR/ApoB48
deficient mice, Vuorio et al. (2014) demonstrated a deficiency in
adventitial lymphatics of descending aorta. RCT rate from the
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peritoneum, measured by injection of radiolabeled-cholesterol
macrophages in the peritoneum, was not different between
sVEGFR3 transgenic x LDLR/ApoB48 and LDLR/ApoB48
deficient mice, although the peritoneal environment is a poor
model for lymphatic transport, given the role of the omentum in
uptake of fluid and cells in a manner seemingly independent
of lymphatics (Yuan et al., 1994). Most importantly, these
two lymphatic deficient transgenic strains had accelerated
atherosclerosis and increased plasma cholesterol and triglyceride
levels compared to lymphatic sufficient controls, indirectly
supporting the role of lymphatic dependent mechanisms in the
removal of cholesterol from the atherosclerotic vessel. What
remains currently unknown is howmodification of ApoA1within
the plaque environment, where dysfunctional HDL has been
documented (Zheng et al., 2004; DiDonato et al., 2013; Huang
et al., 2014), influences cholesterol transport from through the
lymphatics.
In other studies, the cholesterol level of the skin has been
correlated with the increased thickness of carotid intima area
of subjects with (Bouissou et al., 1974, 1982) and without
diagnosed CVD (Bouissou et al., 1974, 1982; Tzou et al., 2005;
Lutgers et al., 2010). Therefore, skin cholesterol level is useful to
identify potential individuals that may undergo atherosclerosis
(Stein et al., 2008). Xanthoma, known as lipid and cholesterol
accumulation in the skin, is induced by foam cell formation with
accumulated lipoproteins, similar to the pathogenic mechanisms
in the early stage of atherosclerosis (Rapp et al., 1983), and poor
lymphatic drainage correlates to xanthoma formation in human
patients (Berger et al., 1972). Relevant to atherosclerotic disease,
deficiency of ApoE in human and mouse promotes development
of xanthoma following prolonged hypercholesterolemia (van Ree
et al., 1995; Feussner, 1996; Moghadasian et al., 2001). Lim
et al. (2009) showed that hypercholesterolemic ApoE deficient
mice, but not young ApoE-deficient mice, had structural and
functional defects in skin lymphatics. These results suggest that
the atherogenic phenotype of ApoE deficient mice may at least
in part be due to defective lymphatic function that develops
in response to hypercholesterolemia (Lim et al., 2009, 2013;
Martel et al., 2013). Interestingly, mice deficient in both ApoA1
and LDLR have significantly increased atherosclerotic plaque
burden and reduced RCT (Moore et al., 2003, 2005). A separate
study found that despite a lack of plasma hypercholesterolemia,
ApoA1/LDLR double deficient mice had substantial cholesterol
accumulation in the skin (Zabalawi et al., 2007). This pathological
change could be normalized by ApoA1 treatment (Wilhelm et al.,
2010) or ectopic macrophage ApoA1 expression (Tavori et al.,
2015), probably due to restored cellular cholesterol efflux out of
the skin.
Conclusion
Over the past 30 years, although observational studies suggest
a hypothesis that higher HDL cholesterol would reduce
cardiovascular events, recent data indicate a system more subtle
and complex than that basic notion. It is widely recognized that
what really matters is cholesterol flux and removal from cells
like macrophages. However, relatively little research examines
the trafficking of HDL into and out of the interstitium. As
trafficking out of the interstitium appears to be dependent upon
functional lymphatics, we suggest that additional research into
the maintenance of lymphatic transport with respect to HDL
trafficking is needed.
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